Tag: David Margolis

Cindy Gay, MD, MPH, and David Margolis, MD, and the UNC HIV Cure Center have launched two ambitious studies that are poised to advance HIV Cure science closer to ending the epidemic. The first uses highly engineered antibody-like molecules to help the immune system find and clear HIV‑infected cells, uniting...

HIV cure strategies that aim to induce viral reactivation for immune clearance leverage latency reversal agents to modulate host pathways, which directly or indirectly facilitate viral reactivation. Inhibition of BET (bromo and extra-terminal domain) family member BRD4 reverses HIV latency, but enthusiasm for the use of BET inhibitors in HIV...

Human Immunodeficiency virus (HIV) infection is regulated by various host cell factors that combine to influence viral transcription and latency. To understand the complex relationship between the host cell and HIV-1 latency, Edward Browne, PhD, Nancie M. Archin, PhD, and David Margolis, MD, performed a lentiviral CRISPR screen that targeted a...

Investigators with the Institute for Global Health and Infectious Diseases (IGHID) participated in the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California, March 9-12. Following are some highlights.   In a CROI preview, Joe Eron, MD, was interviewed for the “Going Anti-Viral” IAS-USA podcast, discussing the...

Antiretroviral therapies (ART) stop HIV replication in its tracks, allowing people with HIV to live relatively normal lives. However, despite these treatments, some HIV still lingers inside cells in a dormant state known as “latency.” If ART is discontinued, HIV will awaken from its dormant state, begin to replicate, and...

HIV/AIDS has been around for approximately 40 years, but many researchers say the end is in sight. The question is, will it be in our lifetime or just around the corner? This is a spotlight on the HIV CURE Center, comprising approximately 55 researchers and students, featuring David Margolis, MD, the...

HIV virus eradication is a complex health challenge due to its long-lived persistence and how it hides in latently infected cells that escape the body’s immune system. Effective HIV treatments have decreased the likelihood of someone developing AIDS, while helping individuals live long and healthy lives without transmission to sexual...

Infectious disease research at the UNC Institute for Global Health and Infectious Diseases (IGHID) attracts unique people driven to make big change in the world. As HIV/AIDS turned 40 in 2021, the world was immersed in a different pandemic, one that brought reminders of the tremendous change science made possible...

The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV. The new awards for the Martin Delaney Collaboratories for HIV Cure Research program, initiated in 2011, further expand the...

By the spring of 2020, the urgency of the COVID-19 pandemic caused many researchers affiliated with UNC’s Institute for Global Health and Infectious Diseases to pivot their studies to focus on testing, treatment and prevention of the SARS-CoV-2 virus. Here, a look at some of the projects underway in the...

Overcoming HIV latency – induction of HIV in CD4+ T cells that lay dormant throughout the body – is a major step toward creating a cure for HIV. For the first time, scientists at UNC-Chapel Hill, Emory University, and Qura Therapeutics – a partnership between UNC and ViiV Healthcare –...